Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 7/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856094 | 1.00 | USP2 (0.44) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL22856599 | 0.89 | PDK1 (0.50) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL22856574 | 0.89 | PDK1 (0.50) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL31493955 | 0.89 | PDK1 (0.50) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL8140489 | 0.86 | PDK1 (0.54) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL17897027 | 0.86 | PDK1 (0.54) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL30962180 | 0.86 | PDK1 (0.59) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL23807943 | 0.85 | USP2 (0.43) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL22856401 | 0.85 | USP2 (0.43) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL23807942 | 0.84 | MEN1 (0.45) | USP2SMN1; SMN2PDK1EPHA2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089916-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2020264490-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089916-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK1, IRAK3 | USP2 398/4885SMN1; SMN2 3491/4885PDK1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.